NorthShore University HealthSystem-Glenbrook Hospital

Summary

NorthShore University HealthSystem-Glenbrook Hospital is a medical facility located in Glenview, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Cancer and other specialties. NorthShore University HealthSystem-Glenbrook Hospital is involved with conducting 133 clinical trials across 237 conditions. There are 16 research doctors associated with this hospital, such as Christopher R. Trevino, Bruce E. Brockstein, Mary T Jenkins Vogel, MD, and Poornima Saha.

Top PIs

Clinical Trials running at NorthShore University HealthSystem-Glenbrook Hospital

Ovarian Cancer

Breast Cancer

Acute Myeloid Leukemia

Cancer

Prostate Cancer

Lung Cancer

Breast cancer

Bladder Cancer

Non-Small Cell Lung Cancer

Esophageal cancer

Biobank Collection

for Cancer

This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.

Recruiting

1 award

N/A

10 criteria

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.

Recruiting

1 award

Phase 2